[1] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Cancer incidence and mortality patterns in Europe:estimates for 40 countries and 25 major cancers in 2018[J].Eur J Cancer, 2018,103:356-387.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6):394-424.
[3] BERRUTI A, AMOROSO V, GALLO F, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy:a meta-regression of 29 randomized prospective studies[J].J Clin Oncol,2014,32(34):3883-3891.
[4] COCKBURN A, YAN J, RAHARDJA D, et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer[J].Hum Pathol, 2014, 45(2):249-258.
[5] CORTAZAR P, ZHANG L, UNTCH M, et al. Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled nanlysis[J].Lancet,2014, 384(9938):164-172.
[6] BOSSUYT V, HATZIS C. The neoadjuvant model and complete pathologic response in breast cancer:all or nothing?[J].JAMA Oncol, 2016,2(6):760-761.
[7] ASANO Y, KASHIWAGI S, GOTO W, et al. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden[J].BMC Cancer,2017,17(1):888-898.
[8] BOSSUYT V, PROVENZANO E, SYMMANS W F, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration[J].Ann Oncol,2015,26(7):1280-1291.
[9] AMIN M B, GREENE FL,EDGE S B, et al. The eighth edition AJCC cancer staging manual:continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J].CA Cancer J Clin,2017,67(2):93-99.
[10] CHOLLET P, ABRIAL C, DURANDO X, et al. A new prognostic classification after primary chemotherapy for breast cancer:residual disease in breast and nodes (RDBN)[J].Cancer J, 2008,14(2):128-132.
[11] BHARGAVA R, DABBS D J, BERIWAL S, et al. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer[J].Mod Pathol,2011,24(3):367-374.
[12] CHOI M, PARK Y H, AHN J S, et al. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy:comparison of pathologic classification systems[J].Breast Cancer Res Treat, 2016,160(3):475-489.
[13] CLARK B Z, FARRUGIA D J, LANDMANN A,et al. Prognostic signifcance of modifed residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant chemotherapy for Breast Cancer[J].Am J Clin Pathol,2018,149(4):332-343.
[14] SYMMANS W F, PEINTINGER F, HATZIS C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J].J Clin Oncol, 2007, 25(28):4414-4422.
[15] DIAZ J, STEAD L, SHAPIRO N, et al. Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. Breast Cancer Res Treat[J].2013,138(1):91-97.
[16] SHARMA P, LO'PEZ-TARRUELLA S, GARCIA-SAENZ J A, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel[J].Clin Cancer Res,2018,24(23):5820-5829.
[17] QUINTELA-FANDINO M, LLUCH A, MANSO L, et al. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer:a window-of-opportunity randomized trial[J].Clin Cancer Res,2017,23(6):1432-1441.
[18] COTTU P, D'HONDT V, DUREAU S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer[J].Ann Oncol. 2018,29(12):2334-2340.
[19] MARTIN M, CHACON J I, ANTON A, et al. Neoadjuvant therapy with weekly nanoparticle albumin-bound paclitaxel for luminal early breast cancer patients:results from the NABRAX study (GEICAM/2011-02), a multicenter, non-randomized, phase Ⅱ trial, with a companion biomarker analysis[J].Oncologist,2017,22(11):1301-1308.
[20] NAIDOO K, PARHAM D M, PINDER S E. An audit of residual cancer burden reproducibility in a UK context[J].Histopathology, 2017,70(2):217-222.
[21] PEINTINGER F,SINN B,HATZIS C,et al.Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy[J].Mod Pathol,2015,28(7):913-920.
[22] SYMMANS W F, WEI C, GOULD R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype[J].J Clin Oncol,2017,35(10):1049-1060.
[23] CAMPBELL J I, YAU C, KRASS P, et al. Comparison of residual cancer burden, American Joint Committee on cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy:results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)[J].Breast Cancer Res Treat,2017,165(1):181-191.
[24] LYMAN G H, SOMERFIELD M R, BOSSERMAN L D, et al.Sentinel lymph node biopsy for patients with early-stage breast cancer:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol, 2017,35(5):561-564.
[25] PILEWSKIE M, MORROW M. Axillary nodal management following neoadjuvant chemotherapy[J].JAMA Oncol,2017,3(4):549-555.
[26] CAUDLE A S, YANG W T, KRISHNAMURTHY S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes:implementation of targeted axillary dissection[J].J Clin Oncol,2016,34(10):1072-1078.
[27] BOSSUYT V,PROVENZANO E,SYMMANS W F, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIGNABCG collaboration[J].Ann Oncol, 2015, 26(7):1280-1291.
[28] BOSSUYT V, SYMMANS W F. Standardizing of pathology in patients receiving neoadjuvant chemotherapy[J].Ann Surg Oncol,2016,23(10):3153-3161.
[29] OLLILA D W, CIRRINCIONE C T, BERRY D A, et al. Axillarymanagement of stage Ⅱ/Ⅲ breast cancer in patients treated with neoadjuvant systemic therapy:results of CALGB 40601(HER2-positive) and CALGB 40603(triple-negative)[J].J Am Coll Surg,2017,224(4):688-694. |
